Skip to content

Search

Showing results for "clinical trials"

Deep or awake removal of laryngeal mask airway in children at risk of respiratory adverse events undergoing tonsillectomy - a randomised controlled trial

We found no evidence for a difference in the timing of the laryngeal mask airways removal on the incidence of respiratory adverse events

Functional differences in airway dendritic cells determine susceptibility to IgE-sensitization

Respiratory IgE-sensitization to innocuous antigens increases the risk for developing diseases such as allergic asthma.

What Influences Parents’ Fear about Children’s Independent Mobility? Evidence from a State-Wide Survey of Australian Parents

To identify factors associated with generalized and stranger-specific PF about CIM, a critical aspect of physical activity.

Airway surface liquid pH is not acidic in children with cystic fibrosis

Modulation of ASL pH has been proposed as a therapy for CF. However, evidence that ASL pH is reduced in CF is limited and conflicting.

The continuity and duration of depression and its relationship to non-suicidal self-harm and suicidal ideation and behavior in adolescents 12–17

Overlap between non-suicidal self-harm and suicidal ideation and behavior in young people with both symptom continuity and symptom duration implicated in this association

Maternal Alcohol Use Disorder and Risk of Child Contact with the Justice System in Western Australia: A Population Cohort Record Linkage Study

Children who were exposed to a maternal alcohol use disorder had significantly increased odds of contact with the justice system.

Increased CTLA-4+ T cells may contribute to impaired T helper type 1 immune responses in patients with chronic obstructive pulmonary disease

Chronic inflammation may expand sub-populations of T cells expressing CTLA-4 in COPD patients and therefore impair T-cell function

The collective impact of rare diseases in Western Australia: An estimate using a population-based cohort

This cohort study provides new evidence of a disparity between the proportion of the population with rare diseases and their combined health-system costs